Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.
- 23 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
- 19 Sep 2017 New trial record